Alkem Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Alkem Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 17 August 2026.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5680, up 1.46% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.16% on the day, quoting at 24468.6. The Sensex is at 78452.78, up 0.21%. Alkem Laboratories Ltd has risen around 6.04% in last one month.

Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 6.86% in last one month and is currently quoting at 25866.25, down 0.24% on the day. The volume in the stock stood at 1.28 lakh shares today, compared to the daily average of 1.58 lakh shares in last one month.

The benchmark July futures contract for the stock is quoting at Rs 5692.5, up 1.13% on the day. Alkem Laboratories Ltd is up 18.31% in last one year as compared to a 4.13% drop in NIFTY and a 16.41% drop in the Nifty Pharma index.

The PE of the stock is 29.05 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Alkem Laboratories announced that the 52th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Alkem Laboratories announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting Rs 350.

Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience.

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.